Cataract Surgery Success in Most Patients Defined by MIPS

Why It Matters

The findings expose a systemic bias in MIPS that could misrepresent surgeon performance and affect reimbursement, urging policymakers to adjust for patient demographics and comorbidities.

Key Takeaways

• MIPS measure 191 excludes ~48% of cataract surgery patients
• Success rate ≥20/40 reaches 90.7% at 90 days
• Older age, Medicare, low income lower odds of success
• Excluding comorbid ocular disease raises success to 95.5%
• Black and Asian patients show higher odds when comorbidities excluded

Pulse Analysis

The Merit‑Based Incentive Payment System (MIPS) is the primary quality‑reporting tool the Centers for Medicare & Medicaid Services uses to evaluate ophthalmic care. Measure 191, which tracks cataract surgery outcomes, deliberately omits patients with chronic ocular comorbidities to simplify performance metrics. While this approach streamlines data collection, the new JAMA Ophthalmology study shows that nearly half of all cataract cases are left out, skewing the picture of surgical success and potentially penalizing providers who treat more complex populations.

Analyzing over 55,000 procedures from 2010‑2023, researchers found that 90‑day visual‑acuity success (≥20/40) exceeds 90% when the full cohort is considered, but jumps to 95.5% once comorbid patients are removed. The gap widens for stricter acuity thresholds, underscoring how case‑mix drives reported outcomes. Socio‑demographic factors also matter: older patients, those on Medicare, and individuals in lower‑income quartiles face lower odds of achieving optimal vision, while Black and Asian patients demonstrate higher odds of success only when comorbidities are excluded, highlighting hidden disparities.

For clinicians and health‑system leaders, the study signals a need to refine MIPS scoring. Incorporating case‑mix adjustments or alternative risk‑adjusted metrics could produce a fairer assessment of surgical quality and safeguard reimbursement streams. Policymakers may also consider expanding the measure to capture patient‑reported outcomes such as glare and contrast sensitivity, offering a more holistic view of post‑operative vision. As value‑based care expands, aligning incentives with equitable, comprehensive data will be essential for maintaining both clinical excellence and financial viability.